Deals
Sanofi Seeks $25 Billion Deal in Asset Talks With Boehringer
- Boehringer's consumer-health assets, Sanofi's Merial in deal
- Sanofi plans to buy back shares with part of proceeds
This article is for subscribers only.
Sanofi is in exclusive talks to swap assets with Germany’s Boehringer Ingelheim GmbH in a 22.8 billion-euro ($25 billion) transaction that would be the largest for the French drugmaker in more than a decade.
Sanofi’s animal-health business, valued at 11.4 billion euros, and Boehringer Ingelheim’s consumer-health operations, at 6.7 billion euros, would be traded, according to a statement on Tuesday. Closely held Boehringer Ingelheim would also pay Sanofi 4.7 billion euros in cash.